

Obesity Market to witness growth by 2032, estimates DelveInsight | Novo Nordisk, Lilly, Boehringer Ingelheim, Novartis

Obesity companies are Novo Nordisk, Eli Lilly, MedImmune, Boehringer Ingelheim, Altimune, Saniona, Novartis, Pfizer, Sciwind Biosciences, Empros Pharma, etc


ALBANY, NEW YORK, UNITED STATES, April 2, 2024 /EINPresswire.com/ -- DelveInsight's "Obesity Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Obesity, historical and forecasted epidemiology as well as the Obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Obesity market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Obesity market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Obesity treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Obesity market.

Request for a Free Sample Report @ [Obesity Market Forecast](#)

Some facts of the Obesity Market Report are:

- According to DelveInsight, Obesity market size is expected to grow at a decent CAGR by 2032.
- In 2021, the total Obesity market size was USD 1,052 million which is expected to rise during the study period (2019–2032).
- Leading Obesity companies working in the market are Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma and others.
- Key Obesity Therapies expected to launch in the market are Semaglutide oral, Tirzepatide,



Tesomet, RZL-012, EMP16, DD01, ZP 8396, ERX-1000, and others.

- On June 2023, Eli Lilly and Company (NYSE: LLY) announced the new phase 2 data from retatrutide, Lilly's investigational molecule being studied for the treatment of obesity. At 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) met the primary endpoint for the efficacy estimand in participants living with obesity or overweight without diabetes, demonstrating a mean weight reduction up to 17.5% (41.2 lb. or 18.7 kg). In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% (57.8 lb. or 26.2 kg)ⁱⁱ at the end of the 48-week treatment duration.
- On June 2023, Pfizer (NYSE: PFE) updated that it is scrapping its once-a-day experimental obesity pill because of concerns about liver safety, but will continue developing its other obesity pill, the twice-daily treatment danuglipron, as it races to rival the success of other weight loss treatments.
- On May 2023, Novo Nordisk (NYSE: NVO) announced positive results from a phase IIIa study, OASIS 1, in the global OASIS program for a once-daily oral formulation of semaglutide in obesity.

Obesity Overview

Obesity is a chronic condition characterized by an excessive accumulation of body fat, leading to adverse health effects and increased risk of various diseases. It is typically defined by a body mass index (BMI) of 30 or higher. Obesity results from complex interactions between genetic, environmental, socioeconomic, and behavioral factors. Sedentary lifestyles, high-calorie diets, and genetic predispositions contribute to its development. Obesity is associated with numerous health complications, including type 2 diabetes, cardiovascular disease, hypertension, certain cancers, and musculoskeletal disorders. Additionally, it can impair quality of life and increase mortality rates. Prevention and management strategies for obesity include dietary modifications, regular physical activity, behavioral therapy, medications, and in severe cases, bariatric surgery. Public health initiatives and policies aimed at promoting healthy lifestyles and reducing obesity prevalence are essential to address this global epidemic and its associated health burdens.

Learn more about Obesity treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr

Obesity Market

The Obesity market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Obesity market trends by analyzing the impact of current Obesity therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Obesity market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition

with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Obesity market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Obesity market in 7MM is expected to witness a major change in the study period 2019-2032.

Obesity Epidemiology

The Obesity epidemiology section provides insights into the historical and current Obesity patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Obesity market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Obesity Epidemiology @ [Obesity Market Dynamics and Trends](#)

Obesity Drugs Uptake

This section focuses on the uptake rate of the potential Obesity drugs recently launched in the Obesity market or expected to be launched in 2019-2032. The analysis covers the Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug.

Obesity Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Obesity market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Obesity Pipeline Development Activities

The Obesity report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Obesity key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Obesity pipeline development activities @ [Obesity Therapies and Drugs](#)

Obesity Therapeutics Assessment

Major key companies are working proactively in the Obesity Therapeutics market to develop novel therapies which will drive the Obesity treatment markets in the upcoming years are Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma and others.

Obesity Report Key Insights

1. Obesity Patient Population
2. Obesity Market Size and Trends

3. Key Cross Competition in the Obesity Market
4. Obesity Market Dynamics (Key Drivers and Barriers)
5. Obesity Market Opportunities
6. Obesity Therapeutic Approaches
7. Obesity Pipeline Analysis
8. Obesity Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Obesity Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Obesity Competitive Intelligence Analysis
4. Obesity Market Overview at a Glance
5. Obesity Disease Background and Overview
6. Obesity Patient Journey
7. Obesity Epidemiology and Patient Population
8. Obesity Treatment Algorithm, Current Treatment, and Medical Practices
9. Obesity Unmet Needs
10. Key Endpoints of Obesity Treatment
11. Obesity Marketed Products
12. Obesity Emerging Therapies
13. Obesity Seven Major Market Analysis
14. Attribute Analysis
15. Obesity Market Outlook (7 major markets)
16. Obesity Access and Reimbursement Overview
17. KOL Views on the Obesity Market
18. Obesity Market Drivers
19. Obesity Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Ankit Nigam

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

Visit us on social media:

[Facebook](#)

Twitter
LinkedIn
Instagram
YouTube

This press release can be viewed online at: <https://www.einpresswire.com/article/700534798>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.